New technology may help patients and providers assess changes in severity of Parkinson disease symptoms more objectively.
Newly approved medications for various types of pain, generalized myasthenia gravis, and Parkinson disease will be fodder for discussion at AAN 2018. Here’s a brief overview of the therapies the FDA has approved within the past 6 months.
Findings from a new study indicate that compared with children who were not exposed to the drug, children with in utero exposure to sodium valproate have lower scores on national tests at age 7 years.
A study undertaken to evaluate the efficacy and tolerability of single pulse transcranial magnetic stimulation (sTMS) for the preventive treatment of migraine has led to an FDA extended indication.
Parkinson disease articles published in 2018 reveal deeper dives into factors that include the impact of sleep and fatigue on symptoms.
What's the link between restrictive anorexia, anorexia nervosa, and binge eating disorder and ASD? This study sheds some light.
What are the risks of birth defects and perinatal outcomes for infants exposed to various AEDs in utero?
Women who have migraines with aura are at increased risk of stroke. Now, a new systematic review suggests that use of combined hormonal contraceptives by these patients raises their stroke risk over and above the already increased risk.
A 5-year study assessed the association between dry eye and comorbid pain conditions in thousands of veterans and here's what they found.
Most people with Parkinson Disease develop cognitive impairment at some point. But this study provides evidence for sex differences in progression to cognitive impairment and dementia.